151 related articles for article (PubMed ID: 19141127)
61. An Investigation of the Relationship Between
Kandemir O; Demir F
Curr Radiopharm; 2024; 17(1):111-116. PubMed ID: 37644744
[TBL] [Abstract][Full Text] [Related]
62. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
63. Effects of intratumoral inflammatory process on 18F-FDG uptake: pathologic and comparative study with 18F-fluoro-α-methyltyrosine PET/CT in oral squamous cell carcinoma.
Kim M; Achmad A; Higuchi T; Arisaka Y; Yokoo H; Yokoo S; Tsushima Y
J Nucl Med; 2015 Jan; 56(1):16-21. PubMed ID: 25476535
[TBL] [Abstract][Full Text] [Related]
64. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.
Lopci E; Toschi L; Grizzi F; Rahal D; Olivari L; Castino GF; Marchetti S; Cortese N; Qehajaj D; Pistillo D; Alloisio M; Roncalli M; Allavena P; Santoro A; Marchesi F; Chiti A
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1954-61. PubMed ID: 27251642
[TBL] [Abstract][Full Text] [Related]
65. Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management.
Kim MP; Correa AM; Hofstetter W; Mehran R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Erasmus JJ; Swisher SG
Ann Thorac Surg; 2015 Feb; 99(2):414-20. PubMed ID: 25497068
[TBL] [Abstract][Full Text] [Related]
66. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis.
Han H; Silverman JF; Santucci TS; Macherey RS; d'Amato TA; Tung MY; Weyant RJ; Landreneau RJ
Ann Surg Oncol; 2001; 8(1):72-9. PubMed ID: 11206229
[TBL] [Abstract][Full Text] [Related]
67. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in hybrid 18F-FDG PET/MRI in non-small cell lung cancer (NSCLC) lesions: initial results.
Heusch P; Buchbender C; Köhler J; Nensa F; Beiderwellen K; Kühl H; Lanzman RS; Wittsack HJ; Gomez B; Gauler T; Schuler M; Forsting M; Bockisch A; Antoch G; Heusner TA
Rofo; 2013 Nov; 185(11):1056-62. PubMed ID: 23860802
[TBL] [Abstract][Full Text] [Related]
68. Noninvasive evaluation of microscopic tumor extensions using standardized uptake value and metabolic tumor volume in non-small-cell lung cancer.
Meng X; Sun X; Mu D; Xing L; Ma L; Zhang B; Zhao S; Yang G; Kong FM; Yu J
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):960-6. PubMed ID: 21440998
[TBL] [Abstract][Full Text] [Related]
69. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
Nair VJ; MacRae R; Sirisegaram A; Pantarotto JR
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):312-8. PubMed ID: 24411602
[TBL] [Abstract][Full Text] [Related]
70. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy.
Tanaka H; Hayashi S; Hoshi H
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e113-7. PubMed ID: 24176011
[TBL] [Abstract][Full Text] [Related]
71. Maximal standardized uptake value on FDG-PET is correlated with cyclooxygenase-2 expression in patients with lung adenocarcinoma.
Shimizu K; Hirami Y; Saisho S; Yukawa T; Maeda A; Yasuda K; Nakata M
Ann Thorac Surg; 2012 Feb; 93(2):398-403. PubMed ID: 22206958
[TBL] [Abstract][Full Text] [Related]
72. Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer.
Christensen JD; Colby TV; Patz EF
Cancer; 2010 Sep; 116(17):4095-102. PubMed ID: 20533438
[TBL] [Abstract][Full Text] [Related]
73. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
[TBL] [Abstract][Full Text] [Related]
74. In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging.
Zegers CM; van Elmpt W; Reymen B; Even AJ; Troost EG; Ollers MC; Hoebers FJ; Houben RM; Eriksson J; Windhorst AD; Mottaghy FM; De Ruysscher D; Lambin P
Clin Cancer Res; 2014 Dec; 20(24):6389-97. PubMed ID: 25316821
[TBL] [Abstract][Full Text] [Related]
75. Diagnostic impact of integrated 18F-FDG PET/MRI in cerebral staging of patients with non-small cell lung cancer.
Deuschl C; Nensa F; Grueneisen J; Poeppel TD; Sawicki LM; Heusch P; Gramsch C; Mönninghoff C; Quick HH; Forsting M; Umutlu L; Schlamann M
Acta Radiol; 2017 Aug; 58(8):991-996. PubMed ID: 28273734
[TBL] [Abstract][Full Text] [Related]
76. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma.
Kaira K; Serizawa M; Koh Y; Takahashi T; Hanaoka H; Oriuchi N; Endo M; Kondo H; Nakajima T; Yamamoto N
Eur J Cancer; 2012 May; 48(8):1244-54. PubMed ID: 22330319
[TBL] [Abstract][Full Text] [Related]
77. Assessment of VEGF-D expression measured by immunohistochemical staining and F-18 FDG uptake on PET as biological prognostic factors for recurrence in patients with surgically resected lung adenocarcinoma.
Zhang L; Higashi K; Ishigaki Y; Ueda Y; Sakuma T; Takegami T; Oguchi M; Xu K; Ohta Y; Nishida H; Tonami H
Ann Nucl Med; 2010 Aug; 24(7):533-40. PubMed ID: 20607627
[TBL] [Abstract][Full Text] [Related]
78. Correlation of [18F]FDG PET activity with expressions of Ki-67 in non-small-cell lung cancer.
Kucukosmanoglu I; Karanis MIE; Unlu Y; Erol M
Nucl Med Rev Cent East Eur; 2022; 25(2):73-77. PubMed ID: 36047292
[TBL] [Abstract][Full Text] [Related]
79. Prediction of recurrence for non-small cell lung cancer by combined analysis of molecular markers and 18F 2-fluoro-2-deoxy-D-glucose positron emission tomography.
Yonechi A; Suzuki H; Sakuma H; Higuchi M; Ohsugi J; Okabe N; Muto S; Teranishi Y; Gotoh M
Fukushima J Med Sci; 2014; 60(1):47-56. PubMed ID: 25030720
[TBL] [Abstract][Full Text] [Related]
80. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in lymph node metastases of non-small cell lung cancer (NSCLC) patients using hybrid 18F-FDG PET/MRI.
Schaarschmidt BM; Buchbender C; Nensa F; Grueneisen J; Gomez B; Köhler J; Reis H; Ruhlmann V; Umutlu L; Heusch P
PLoS One; 2015; 10(1):e0116277. PubMed ID: 25574968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
